Neonatal onset multisystem inflammatory disease (NOMID) is a serious clinical condition characterized by a systemic inflammatory response that occurs in neonates. These infants may present with a variety of symptoms including but not limited to fever, hypotension, metabolic disturbances, and changes in the functioning of various organs. One of the major threats of this disease is the high probability of death without timely diagnosis and adequate treatment. NOMID may be caused by various antecedents including infectious agents, genetic predisposition, and environmental exposures. Understanding the pathogenesis, clinical presentation, and treatment options for this disease is important to improve the prognosis of neonates susceptible to this condition.
History of the disease and interesting historical facts
Multisystem inflammatory disease was first described in the medical literature in the mid-20th century. Although it can be caused by various infections, its association with COVID-19 has attracted the attention of researchers and clinicians in recent years. In the 1980s, it became known that MSDS could occur as a severe form of reactive inflammation, as indicated by numerous studies. In 2020, the World Health Organization identified this disease as a separate nosological entity due to its manifestations in children infected with SARS-CoV-2. Many years of research and observations have made it possible to identify key aspects of pathogenesis and clinical presentation, which contributed to the development of more effective diagnostic and therapeutic methods.
Epidemiology
The prevalence of multisystem inflammatory disease in neonates remains an active research topic. According to current epidemiological studies, the incidence rate varies depending on the region and time of year. For example, during the COVID-19 pandemic, the incidence of MSID in children increased to 3-4% of the total number of hospitalizations with inflammatory diseases. Note: according to data from different countries, there is also a comparable incidence of MSID caused by other infections, such as viral and bacterial infections. In the neonatal age group, this diagnosis is recorded in 8-12 cases per 1000 live births, and an increase may be observed among children with a weakened health condition.
Genetic predisposition to this disease
In recent years, increasing evidence has pointed to a genetic predisposition to multisystem inflammatory disease. Studies show that certain mutations in genes involved in the immune response may increase the risk of developing MSDS. For example, the IL-1β and TNF-α genes show increased activity in response to inflammatory stimuli in neonates predisposed to the disease. At the same time, studies of single nucleotide polymorphisms (SNPs) indicate that some polymorphisms are directly correlated with the risk of developing severe forms of MSDS during viral infections. This discovery requires further research to better understand the mechanisms underlying the immune response disorder.
Risk factors for the development of this disease
The unjustified influence of the environment on the health of the newborn raises the question of risk factors that contribute to the development of multisystem inflammatory disease. The main factors include:
- Presence of infectious diseases in the mother during pregnancy;
- History of previous allergic reactions or autoimmune diseases;
- Exposure to toxic chemicals, including pesticides and heavy metals;
- Lack of vaccination in a newborn;
- Socioeconomic factors such as poor living conditions and health care.
These factors can act either individually or in combination, creating conditions for the formation of an inflammatory process in newborns.
Diagnosis of this disease
Diagnosis of multisystem inflammatory disease requires a comprehensive approach, since the clinical picture may vary depending on the etiology. The main symptoms to pay attention to are:
- Fever, sometimes reaching high values;
- Skin rashes and conjunctivitis;
- Respiratory failure;
- Impaired function of organs such as the liver and kidneys.
Multiple laboratory tests are important to confirm the diagnosis, including a complete blood count with C-reactive protein and interleukins, and microbiological tests. Radiological examinations (ultrasound, x-ray) may be useful to assess the condition of organs. Differential diagnosis is necessary to exclude infectious diseases, autoimmune disorders, and other causes of systemic inflammation.
Treatment
General treatment of multisystem inflammatory disease includes inpatient observation and supportive care. Pharmacological treatment often focuses on the use of anti-inflammatory agents such as glucocorticosteroids. In case of bacterial infection, antibiotic therapy is necessary to eliminate the infection. Surgical treatment may be required if complications such as peritonitis occur. There are also cases of successful use of anti-cytokine therapies and immunoglobulins in seriously ill patients. Each case requires an individual approach taking into account the condition of the newborn, the characteristics of the pathology and possible concomitant conditions.
List of medications used to treat this disease
Medications used to treat multisystem inflammatory disease vary depending on the severity of the condition and its etiology:
- Glucocorticosteroids (for example, prednisone);
- Nonsteroidal anti-inflammatory drugs (eg, ibuprofen);
- Antibiotics (eg, cephalosporins);
- Immunoglobulins;
- Anticytokines (eg, tocilizumab).
The effectiveness of treatment depends on the timeliness of the start of therapy and strict adherence to medical recommendations.
Disease monitoring
Monitoring of neonates with multisystem inflammatory disease requires regular observation and testing to assess the dynamics of the inflammatory process. Monitoring steps include:
- Regular measurements of body temperature;
- Conducting laboratory tests for the level of inflammatory markers;
- Evaluation of the function of organs and systems using ultrasound and other methods;
- Monitoring for clinical signs of complications.
The prognosis depends on the speed of care and the presence of concomitant diseases, which can significantly change the outcome. Complications may include multiple organ failure, neurological disorders, and other serious conditions.
Age-related features of the disease
Multisystem inflammatory disease has its own characteristics in different age groups. In newborns, this condition may manifest itself more vividly with pronounced systemic manifestations. In older children, less pronounced symptoms are often observed, which can complicate early diagnosis. In adolescents, the transition to a state of remission may occur more quickly, but the incidence of associated autoimmune processes is higher. Assistance and monitoring should be age-appropriate, which requires a personalized approach to treatment and rehabilitation.
Questions and Answers
- What are the main symptoms of multisystem inflammatory disease in newborns? The main symptoms include fever, rash, respiratory failure and organ dysfunction.
- What risk factors may contribute to the development of this disease? Risk factors include maternal infectious diseases, toxic exposures, genetic predisposition and social conditions.
- What is the role of genetic factors in the development of MSDS? Genetic predisposition, particularly mutations in genes that regulate the immune response, is important for susceptibility to the disease.
- How is this disease diagnosed? Diagnosis includes tests for inflammatory markers, laboratory and radiological studies, and differential diagnosis.
- What are the basic principles of treatment for multisystem inflammatory disease? Treatment includes the use of anti-inflammatory drugs, antibiotics if necessary, and supportive therapy, taking into account the individual characteristics of the patient.
